Fig. 2: IHC and immune signature analysis. | npj Breast Cancer

Fig. 2: IHC and immune signature analysis.

From: A phase Ib/II trial of atezolizumab with cobimetinib or idasanutlin in metastatic estrogen receptor positive breast cancer

Fig. 2: IHC and immune signature analysis.

A p21 and HLA-ABC were evaluated via multiplexed IHC, and TILs were scored on H&E. Representative images for each assay. B Results are presented for each treatment arm pre- and post-treatment with idasanutlin (idasa) or cobimetinib (cobi). C Relative fractions of immune cells pre- and post-treatment with cobimetinib and idasanutlin. D Changes in resting memory CD4 T cell abundance, M2 macrophage abundance, and monocyte abundance with cobimetinib treatment. E Changes in activated dendritic cell abundance and mast cell abundance in the idasanutlin treatment arm. F Ras/MEK and chemokine gene score changes in patients before and after treatment with either cobimetinib or idasanutlin.

Back to article page